The purpose of this study is to understand the effects of intrathecal ziconotide (an
experimental pain medication) when the dose is slowly increased over a 3-week period in
patients with severe chronic pain. During the weaning phase, the study will also gather
information about switching from other intrathecal or IT medication (slowly pumped directly
into the space around the spine) to other systemic pain medication (by mouth or through the
skin using a patch). After being weaned off current IT medication, patients will be placed on
IT ziconotide or placebo (non-active substance) as well as being allowed a stable dose of
systemic pain medications.
Patients who complete this study may be eligible for long-term ziconotide therapy via
extension protocol ELN92045-352.